Table 1. Overview of currently approved compounds.
Compound | Organization | Disease | Indication |
---|---|---|---|
Ipilimumab (1,2) | FDA, EMA | Cutaneous melanoma | Advanced unresectable melanoma |
FDA | Adjuvant treatment of patients with melanoma with involvement of regional lymph nodes, after complete resection including total lymphadenectomy | ||
Nivolumab (1,2) | EMA, FDA | Cutaneous, melanoma | Advanced disease; unresectable or metastatic |
EMA | NSCLC | Advanced disease squamous histology | |
FDA | Renal cell carcinoma, NSCLC | Advanced disease | |
Advanced disease, non squamous and squamous histology | |||
Pembrolizumab (1,2) | EMA, FDA | Melanoma | Advanced disease: unresectable or metastatic |
FDA | NSCLC | Metastatic, PD-L1 expressing, with disease progression on or after platinum-containing chemotherapy | |
Nivolumab + ipilimumab (1) | FDA | Melanoma | Advanced disease |
FDA, Food and Drug Administration; EMA, European Medicines Agency; NSCLC, non-small cell lung cancer.